NEXVAP creates “R-Evolutionary lifestyle device” for medical drugs and nicotine replacement therapies. NEXVAP needs to raise 13 to 15 million euros over a three year period to sustain its development.

  • Many people worldwide are severely affected by smoking related diseases – Cigarette market declines continuously in favour of E-cigarette growth
  • Others are impacted by the use of cumbersome medical devices to inhale medicines
    – Medical respiratory device market growth is limited by lack of products innovationBusiness Opportunity

• Turning smoking cessation & drug inhalation into an enjoyable and safer habit is key – E-cigarette market expected to grow to $ 50 bn in 2025 and Nicotine Replacement

Therapy market estimated to reach $ 22 bn in 2024
– All-in-one inhalator will expand the scope of medicines administration


Developing and selling consumer-focused, life-style oriented devices
for fast and deep lung deposition of nicotine for Nicotine Replacement Therapies and medically approved drugs

Discover more by video:  httpss://



About Author

Bérengère Miffon

Bérengère est active dans la communication depuis plus de 10 ans. Ses diverses expériences en Suisse et à l'international en communication institutionnelle, communication de marque et de service, stratégie digitale et communication de start-up lui permettent aujourd'hui d'avoir une vision globale et efficace de la communication et du travail de chef de projet qu'elle est heureuse de mettre au service du Réseau.

Leave A Reply